RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Durham, NC · Fayetteville, NC · Greensboro, NC · +173 more sites